Company / Shareholders' Equity
10x Genomics, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$796.3M
FY2025
5-year range
$710.1M / $817.6M
FY2021-FY2025
Trend
+12.1%
vs FY2024
Sector context
#95 of 166
Health Care
What the data says
At $796M, 10x Genomics, Inc.'s shareholders' equity ranks #95 of 166 in the Health Care sector. Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $796M.
Based on SEC 10-K filings.
$796M in FY2025 with a 5-year CAGR of +1.5%.
Improved from $741M to $796M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -0.4%
- 5-Year CAGR
- +1.5%
- 10-Year CAGR
- -
Sector benchmark
#95 of 166 in Health CareTop 57% of 166This company $796.3M Sector average $5.3B
▼
-84.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 12.1% year-over-year.
- Ranks #95 out of 166 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $796.3M | +12.1% |
| FY2024 | $710.1M | -4.2% |
| FY2023 | $741.0M | -8.0% |
| FY2022 | $805.7M | -1.4% |
| FY2021 | $817.6M | +10.6% |
| FY2020 | $739.1M | +75.9% |
| FY2019 | $420.1M | +291.0% |
| FY2018 | -$220.0M | -95.5% |
| FY2017 | -$112.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026